Cargando…
Pharmacologic therapies for diabetic retinopathy and diabetic macular edema
Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of blindness in the working-aged population of most developed countries. The increasing number of persons with diabetes worldwide suggests that DR/DME will continue to be major contributors to vision loss and associated fu...
Autores principales: | Rechtman, Ehud, Harris, Alon, Garzozi, Hanna J, Ciulla, Thomas A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704543/ https://www.ncbi.nlm.nih.gov/pubmed/19668515 |
Ejemplares similares
-
Pharmacology of Corticosteroids for Diabetic Macular Edema
por: Whitcup, Scott M., et al.
Publicado: (2018) -
Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
por: Everett, Lesley A., et al.
Publicado: (2021) -
Current Treatments and Innovations in Diabetic Retinopathy and Diabetic Macular Edema
por: Gonzalez-Cortes, Jesus H., et al.
Publicado: (2022) -
Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema
por: Markan, Ashish, et al.
Publicado: (2020) -
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss
por: Lee, Ryan, et al.
Publicado: (2015)